breast positioning Articles
-
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study (American Society of Clinical Oncology)
Worldwide, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in women, with over 650,000 deaths in 2020.1,2 Human epidermal growth factor receptor 2 (HER2)-targeted agents have improved outcomes in HER2-positive breast cancer, but most patients in first-line therapy do not respond to current therapies, eventually relapse or develop ...
-
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly ...
-
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer ...
-
Representative structures of FDA-approved ADCs
Since they were originally explored in animal models in the 1960s, antibody-drug conjugates (ADCs) have seen many booms. The initial ADC clinical studies took place in the 1980s, and Mylotarg, the first ADC drug, was approved in 2000. The removal of Mylotarg, however, came as a huge shock to the industry, and it was relaunched in 2017. The launch of a number of clinically and commercially ...
-
Three generations of ADC: Nearly a decade of development-PII
Kadcyla and second-generation non-cleavable linkers Alternative linker design methodologies are still under development. Immunogen discovered a very powerful ADC by an accidental discovery. The lysine residue of trastuzumab is linked to DM1 via a non-cleavable linker containing N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), an ADC (T-DM1, Kadcyla) authorized by the FDA in ...
-
Infiltrating Ductal Carcinoma (IDC) - Case Study
Patient with positive family history of breast cancer and ovarian cancer. September 2003 mammogram reported benign micro calcifications. August 2007 patient presented with a palpable mass in lateral aspect of left ...
-
What are the ADC drugs?
Antibody-drug conjugates (ADCs) continue to rise at home and abroad, but ADCs are not a new thing. Why has ADC been surging for so many years? What kind of magic power it contains, and what makes its growth path so tortuous? Let's take a brief look at the magical "magic bullet"-ADC. ADC (antibody-conjugated drug) is not a new concept. As early as the early 20th century, the Nobel Prize winner ...
By BOC Sciences
-
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of Advanced Breast Cancer
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer – that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you